What is Elicio Therapeutics Price-to-Operating-Cash-Flow?
As of today (2024-06-06), Elicio Therapeutics's share price is $7.98.
Elicio Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.88. Hence, Elicio Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Elicio Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:
Elicio Therapeutics's Cash Flow from Operations per share for the
three
months ended in Mar. 2024 was $-1.18.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.88.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -46.70% per year.
During the past 5 years, Elicio Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was -22.90% per year. The lowest was -46.70% per year. And the median was -34.80% per year.
Elicio Therapeutics Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Elicio Therapeutics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elicio Therapeutics Price-to-Operating-Cash-Flow Chart
|
Elicio Therapeutics Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
- |
- |
- |
- |
- |
|
Elicio Therapeutics Quarterly Data
|
|
Dec19 |
Mar20 |
Dec20 |
Mar21 |
Dec21 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Elicio Therapeutics's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Elicio Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicio Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Elicio Therapeutics's Price-to-Operating-Cash-Flow falls into.
Elicio Therapeutics Price-to-Operating-Cash-Flow Calculation
Elicio Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 7.98 | / | -5.884 |
| = | |
Elicio Therapeutics's Share Price of today is $7.98.
Elicio Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.88.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Elicio Therapeutics (Elicio Therapeutics) Business Description
Traded in Other Exchanges
Address
One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA, USA, 02139
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.
Executives
| Yekaterina Chudnovsky |
director |
C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
| Robert R Ruffolo |
director |
|
| Peter Demuth |
officer: Chief Scientific Officer |
C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
| Assaf Segal |
director |
C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
| Annette Matthies |
officer: Chief Business Officer |
ONE KENDALL SQUARE, BUILDING 1400 WEST, SUITE 14303, CAMBRIDGE MA 02139 |
| Robert Connelly |
director, officer: CEO, President and Director |
1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102 |
| Julian Adams |
director |
C/O GAMIDA CELL, 673 BOYLSTON STREET, 4TH FLOOR, BOSTON MA 02116 |
| Christopher Haqq |
officer: See Remarks |
C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
| Carol Gail Ashe |
director |
C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3 |
| Brian Piekos |
officer: Chief Financial Officer |
C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
| Karen J Wilson |
director |
C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
| Gilbert S Omenn |
director |
AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
| Gregory S Curhan |
officer: See Remarks |
600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108 |
| Itzhak Goldberg |
officer: See Remarks |
51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553 |
| John F. Neylan |
officer: See Remarks |
750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Elicio Therapeutics (Elicio Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELTX has been successfully added to your